15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Current situation, causes, and countermeasures to NIP vaccine shortages in Guangzhou, China

      article-commentary

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          From 2017 to 2018, Guangzhou experienced a shortage in 3–6 types of National Immunization Program (NIP) vaccines. To evaluate the current situation and causes of the NIP vaccine shortage, we analysed the duration, intensity and causes of the shortage from data in the vaccine information system of the Guangzhou Center for Disease Control and Prevention; we also proposed countermeasures to resolve the shortage. In 2017, there were shortages of three types of NIP vaccines in Guangzhou. The most affected vaccines were inactivated poliovirus (IPV) vaccine and meningococcal group AC (MenAC) vaccine, accounting for 39.5% and 16.5% of the reported shortages, respectively. In 2018, the shortage extended to six vaccine types; the most affected were diphtheria, tetanus and pertussis (DTP) vaccine, MenAC vaccine, and Bacille Calmette Guerin (BCG) vaccine. The four main causes for the shortage were: 1) an insufficient production capacity; 2) a delay in batch issuance; 3) vaccine-related events; and 4) an extended bidding procurement cycle. Four solutions are proposed: 1) expand production output; 2) exempt creditworthy enterprises from batch inspections; 3) establish alternative enterprises and emergency use authorizations; and 4) establish public health funds and stockpile storage systems.

          Related collections

          Most cited references9

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Comparative Estimation of Coverage between National Immunization Program Vaccines and Non-NIP Vaccines in Korea

          This study aimed to describe the differences in vaccination coverage between National Immunization Program (NIP) vaccines and non-NIP vaccines in Korea and to identify factors affecting the difference. Nationwide face-to-face interview-based questionnaire survey among randomly selected 4,374 participants aged 7-83 months was conducted. Vaccination coverage analyzed according to the birth cohorts, geographic areas, and socio-demographic characteristics. We found that NIP vaccines recorded higher primary vaccination coverage compared to non-NIP vaccines (95.9%-100% vs 30.7%-85.4%). The highest rate was Haemophilus influenzae type b (Hib) vaccine (85.4%), which was introduced in 1996, and the lowest rate was rotavirus vaccine (30.7%), which was introduced recently. On multivariate analysis, having a sibling were significantly associated with lower uptake of Hib vaccine, pneumococcal conjugate vaccine (PCV), and rotavirus vaccine; while, older mother's age and attendance to daycare center were significantly associated with lower uptake of PCV and rotavirus vaccine (P < 0.001). We found differences in the vaccine coverage rate between NIP vaccines and non-NIP vaccines; and the data suggests potential disparity in accessing non-NIP vaccines in Korea. Expansion of NIP to include non-NIP vaccines can provide better protection against the diseases through increased coverage.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            The Australian model of immunization advice and vaccine funding.

            The Australian Government has implemented new arrangements for public funding of vaccines over the past 5 years. By utilising the standard Pharmaceutical Benefits Advisory Committee (PBAC) application process, whether for funding under the National Immunisation Program Schedule (NIP) or under the Pharmaceutical Benefits Scheme (PBS), a predictable and transparent process for vaccine funding recommendations has been established. This process uses the high-level technical resources available through the Australian Technical Advisory Group on Immunisation (ATAGI) to ensure that both vaccine manufacturers and the PBAC are optimally informed about all relevant aspects of population benefits and delivery of vaccines. ATAGI has a long-standing and mutually beneficial dialogue with State and Territory Governments, providers, and vaccine manufacturers to ensure that pipeline awareness, supply issues, and all relevant scientific and clinical details are well understood. Copyright © 2010 Elsevier Ltd. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Vaccine supply problems: a perspective of the Centers for Disease Control and Prevention.

              Although immunization is one of the great public health achievements, continued success depends on an available supply of the vaccines that are recommended for routine use. Beginning in 2000, the United States experienced vaccine supply disruptions of unprecedented scope and magnitude. Although most of the supply disruptions have been resolved, it appears that a fragile vaccine supply will be part of the immunization environment in the United States for the foreseeable future. Here, we describe the perspective of the Centers for Disease Control and Prevention on the recent supply disruptions and the methods used to manage vaccine shortages. The present article focuses on routine pediatric vaccines, including influenza virus vaccine.
                Bookmark

                Author and article information

                Journal
                Hum Vaccin Immunother
                Hum Vaccin Immunother
                KHVI
                khvi20
                Human Vaccines & Immunotherapeutics
                Taylor & Francis
                2164-5515
                2164-554X
                2020
                12 August 2019
                12 August 2019
                : 16
                : 1
                : 76-79
                Affiliations
                [a ]Guangzhou Center For Disease Control And Prevention , Guangzhou, China
                [b ]Department of Anesthesiology, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences , Guangzhou, Guangdong, China
                Author notes
                CONTACT ZhiQun Li 992805123@ 123456qq.com Guangzhou Center For Disease Control And Prevention , No.1, Qide Rd, Jiahe, Baiyun, Guangzhou 510440, China
                [*]

                These authors contributed equally to this work and should both be list as the first author.

                Article
                1644883
                10.1080/21645515.2019.1644883
                7012185
                31403888
                f98c5e52-d624-4fa1-ab1e-51b990a2ba6a
                © 2019 Guangzhou Center for Disease Control and Prevention. Published with license by Taylor & Francis Group, LLC

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                Page count
                Tables: 2, References: 15, Pages: 4
                Product
                Categories
                Commentary

                Molecular medicine
                nip vaccine,shortage,cause,inventory reserve,countermeasures
                Molecular medicine
                nip vaccine, shortage, cause, inventory reserve, countermeasures

                Comments

                Comment on this article